Have you seen our new ‘How I treat…’ features? Become a member (it’s free!) and discover the latest advice from fellow clinicians here >>>

CHRYSALIS: Phase I study demonstrates anti-tumor activity of amivantamab in METex14-mutated NSCLC

Written by Louis Gautier, Future Science Group

ZUMA-7 trial

Recent results from the Phase I study show that amivantamab (Rybrevant®), which targets mutations in the mesenchymal-epithelial transition gene, is safe and triggers positive responses in 64% of patients. Phase I data from the trial is due to be presented at the upcoming IASLC 2021 World Conference on Lung Cancer (September 8–14) and shows that amivantamab, which targets mutations in the mesenchymal-epithelial transition gene, is safe and triggers positive responses in 64% of evaluable NSCLC patients. Around 3% of lung adenocarcinoma patients carry mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations, which result in hyperactivation of the MET receptor and...

To view this content, please register now for access

It's completely free